In clinical medicine, the GVHD syndrome has traditionally been subdivided into two syndromes: acute GVHD and chronic GVHD. [9] [10][11] [12] Acute GVHD develops in 30-60% of There have been many advances in the prevention and treatment of GVHD, including cyclosporine, FK506, recipients of histocompatible sibling-matched allografts, and mortality due directly or indirectly to GVHD may reach and combination therapies. This syndrome, however, continues to account for significant morbidity and mor-50%. [13] [14] [15] Younger subjects, or those with younger donors, develop GVHD less frequently than older recipients of allotality after allogeneic transplantation. With the expanded use of matched unrelated as well as misgeneic bone marrow. [16][17][18][19][20] Even with the use of potent immune suppression, more than half the patients who matched related donors, the increase in incidence and severity of GVHD poses a new clinical challenge. Many receive unmanipulated marrow grafts from histocompatible donors develop GVHD; the risk is higher with histocompatof the newer agents discussed in this paper may have a role in the future as therapy for acute GVHD. The ible donors who are matched but unrelated, and histoincompatible (unmatched) yet related donors and the use of such evaluation of these new agents and the approach to be taken is hampered by the realization that most patients alternative donors appears to be increasing. [21] [22] [23][24][25][26][27][28] [29] [30] Chronic GVHD develops in 35-50% of patients after transplant have received and are relatively refractory to standard therapies. Clinical trials must be performed earlier in either as an extension of acute GVHD (progressive onset), after resolution of acute GVHD (quiescent onset), or withthe course of the syndrome to establish the role of these compounds. Newer strategies are likely to include the out preceding acute GVHD (de novo onset). [31] [32] [33] [34] [35] [36] GVHD in the human setting was hardly recognized when use of sequential therapy directed at blocking endogenous cytokines followed by blocking alloreactive donor clinical transplantation was first undertaken. Subsequently, techniques of HLA typing and other advances have cells, and immunologic advances such as the induction of tolerance. What impact, if any, such therapy may changed the approach to transplant. Over the past 25 years, the diagnosis, prophylaxis, and treatment of GVHD have have on amelioration of a graft-versus-leukemia effect remains unknown.
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evolved slowly, including the recognition that the GVHD syndrome is not entirely attributable to the immunologic Keywords: graft-versus-host disease; cyclosporine; prednisone; transplantation; cytokines; monoclonal antiresponse of major histocompatibility differences between donor and recipient. This review focuses on new clinical bodies and experimental developments in the treatment of acute GVHD, examples of which are shown in Table 1 . Although it is necessary to provide some discussion regarding therapy Graft-versus-host disease (GVHD) continues to be a major for chronic GVHD and prophylaxis of GVHD, these complication after allogeneic bone marrow transplantation, subjects will not be examined extensively. even when the donor is a sibling who is genotypically identical at the major histocompatibility (HLA) locus and the recipient is given potent immunosuppression. [1] [2] [3] [4] [5] The Pathophysiology of GVHD GVHD reaction is manifest by erythroderma, generalized wasting, diarrhea, jaundice, and ultimately, death; the histoAcute GVHD initially was perceived as infiltration by pathological changes have been well-described.
(3) the recipient must be incapable of mounting an immune the 'cytokine storm' reaction of GVHD are shown in Table 2 . response to destroy the transplanted cells. 8 , 37 Gowans 38 and McGregor 39 demonstrated that the cells responsible for the GVHD can develop in the course of (1) bone marrow or peripheral blood progenitor (hematopoietic stem cell) trans-GVHD syndrome were small lymphocytes derived from allogeneic donor bone marrow. It has been shown that acute plantation, (2) transfusion of unirradiated blood products (transfusion-associated GVHD), or (3) solid-organ trans-GVHD is initiated by donor-derived, alloreactive cytotoxic T lymphocytes (CTLs, CD8
+ lymphocytes) and lymphoplantation involving organs containing lymphoid tissue. This review will deal with the first two situations. kine-secreting T helper lymphocytes (HTLs, CD4 + lymphocytes). 40 The extent of histoincompatibility between As understanding of the pathogenesis of GVHD has grown, therapeutic strategies have been modified. 63 It has donor and recipient, the presence of alloreactive, hostspecific donor T cells, and the number of T lymphocytes been proposed that immunosuppression (either via T cell depletion of the graft and/or administration of immunosuppresent in the inoculum correlate with the incidence and severity of GVHD. [41] [42] [43] Donor lymphocytes traditionally pressive therapy to the host after the transplant, ie posttransplant immunosuppression) with its marked propensity were thought to recognize differences in major host histocompatibility antigens leading to a graft-versus-host reacfor increasing opportunistic infections, be replaced by specific anti-cytokine therapy. [64] [65] [66] [67] Clinical trials have begun to tion. More recently, disparities in minor histocompatibility antigens between donor and recipient, inherited indepenaddress this question, although the efficacy of anti-cytokine therapy is still uncertain (see below). dently of HLA genes, were demonstrated to elicit a GVHD reaction. [44] [45] [46] This reaction is then amplified by elaboration of cytokines (see below). Billingham's requirement for an immunoincompetent host has been revised recently, since Acute graft-versus-host disease GVHD has been described experimentally and clinically after infusion of either syngeneic (identical twin) bone mar-
The clinical spectrum of GVHD was described clinically more than two decades ago. 31, [68] [69] [70] [71] Acute GVHD usually row or autologous bone marrow. [47] [48] [49] [50] [51] [52] [53] The recipient must either express tissue antigens not present in the donor, or becomes manifest within 20-40 days of marrow infusion, although potent immunosuppressive agents such as cyclothe host must exhibit an inappropriate recognition of selfantigens, ie an autoimmune process. 54 In addition, immusporine may delay onset by several months. 72 Acute GVHD is graded clinically using a standardized system which takes nohistochemical analysis of the effector cells in the GVHD reaction suggest these cells are natural killer cells rather than mature T cells. 55, 56 into account varying clinico-pathological involvement ducts and is characterized by a scaly, maculopapular, erythematous rash, high fever, diarrhea, and liver function by different organs. While there is general acceptance of this system, there are minor differences among centers abnormalities, as well as pancytopenia. As is the case with 'classic' acute GVHD, any of these features may present in the criteria used to assess the degree of organ involvement. 31, [73] [74] [75] [76] [77] The traditional method for grading as the predominant clinical sign. TA-GVHD often occurs after the transfusion of blood acute GVHD was developed by Glucksberg and colleagues 77 in 1974, based on 61 patients. Recently, Rowlings products shown by histocompatibility testing to be the same immunophenotype as the bone marrow and peripheral and co-workers 78 compared the association of acute GVHD and transplant outcome in 2881 adult patients receiving blood cell donor. Specifically, the clinical features are consistent with the host's inability to eliminate viable donor T HLA-identical sibling transplants for leukemia using a newly developed Severity Index which takes into account lymphocytes present in the transfused blood product. For the syndrome to occur, the recipients ordinarily are HLA variability in prognosis within Glucksberg grades. They demonstrated the utility of this system in an independent heterozygous for an HLA haplotype that is shared with an HLA homozygous donor. For a long time it was thought patient population, and are comparing the Glucksberg grading system with the Severity Index in a prospective trial that the observed frequency of TA-GVHD was much lower than the estimated probability for this donor/recipient comconducted by the French Society for Bone Marrow Transplantation.
bination. Elegant mathematical models developed to estimate TA-GVHD risk, however, are in better agreement with the clinical experience. 85 Furthermore, it is likely that functioning recipient CD8 and NK cells play a central role Chronic graft-versus-host disease in the down-regulation of TA-GVHD development in recipients. 86 Recent advances in therapeutic modalities, Chronic GVHD presents a clinical pattern which usually differs from acute GVHD, ie mesenchymal rather than episuch as the potent T cell suppressor, fludarabine, may be responsible for the recent reports of TA-GVHD in chronic thelial tissues are involved more commonly. Most classifications are based on the extent of disease and performance lymphocytic leukemia patients. 87, 88 TA-GVHD has been reported after transfusion of any score.
32, 79 Chronic GVHD is a multi-organ disorder in which the severity of individual organ involvement does cellular blood product; blood components such as fresh frozen plasma and cyroprecipitate have not been associated not correlate well with the overall survival; the patient's functional performance is a better indicator of survival. 31, 36 with the syndrome. 84 Freezing removes almost all lymphocytes from the blood product, thus significantly minimizing Chronic GVHD is categorized as either limited (localized skin involvement and/or hepatic dysfunction) or extensive; the risk of initiating TA-GVHD. It must be emphasized that there is an extremely high fatality rate for established TAthe latter is associated with a worse prognosis. Such a staging system, however, is not of much value since few GVHD, reaching 90% in some reports. 84 Because of the very high early mortality, chronic GVHD secondary to patients have limited disease.
Understanding of the pathophysiology of chronic GVHD blood transfusion has only rarely been reported. 89 TA-GVHD usually develops in recipients given at least has lagged behind that for acute GVHD. While some investigators believe that chronic GVHD is merely a late 10 7 lymphocytes per kg recipient weight, 90 although rare reports have implicated TA-GVHD with as few as 8 × 10 4 expression of the alloreactivity causing acute GVHD, others postulate that chronic GVHD represents dysfunclymphocytes per kg. 91 Although the condition is almost uniformly fatal in spite of therapy with high doses of corticotional immune reconstitution through the generation of autoreactive clones. 9, 36, 80 Data from experimental systems steroids and cyclosporine, there have been occasional reports of spontaneous resolution. 92 Furthermore, experiof autologous GVHD support this hypothesis since specific class II donor anti-donor autoreactive T cells can be demonmental approaches using monoclonal antibodies such as anti-CD3 (OKT3) and cyclosporine have met with some strated in both mice and humans who have chronic GVHD. This review will not address the therapy of chronic success. 93 Fortunately, prevention of TA-GVHD is readily and GVHD.
most effectively accomplished using gamma-irradiation of cellular blood products. 94 A dose of at least 2500 cGy generally is adequate to inactivate donor lymphocytes and preTransfusion-associated graft-versus-host disease vent TA-GVHD; this radiation dose does not significantly impair granulocyte and platelet function, although red cells Transfusion-associated GVHD (TA-GVHD) is predominantly associated with infusion of unirradiated blood prodo sustain detectable damage. 95 The 2500 cGy dose of gamma irradiation is remarkably effective, 96 although there ducts. 81 Historically, this syndrome was recognized over 20 years ago and the initial reports described its occurrence in have been rare reports of TA-GVHD in patients given irradiated blood products. 97, 98 It is estimated that 15% of children who had immunodeficiency disorders. 82, 83 Subsequently, this condition has been described in considerable institutions performing allogeneic or autologous bone marrow transplantation do not regularly irradiate cellular prodetail, and approximately 150 patients have been reported in the literature. 84 Patients may be either immunocomproducts for transplant recipients, probably due to unavailability of adequate irradiation facilities. 97 In general, bone mised, ie immunodeficiency disorder or hematologic malignancy, or immunocompetent, ie newborns. The syndrome marrow transplantation should only be performed at centers capable of irradiating all cellular blood components. Leukousually occurs 4-30 days after transfusion of blood pro-cyte filtration devices can remove more than 99% of lymincidence of GVHD, although cyclophosphamide was never compared directly to methotrexate. It is interesting phocytes and are readily available; however, this method may not be as effective as gamma irradiation, since the to note, however, that none of these studies compared any of these agents to a 'no prophylaxis' arm. residual lymphocyte 'load' can be associated with TA-GVHD after transfusion.
99
The next agent used to prevent GVHD was anti-thymocyte globulin (ATG), which in some trials was effective in treating this condition. Two studies compared methotrexate prophylaxis to methotrexate plus ATG.
107,108 These investiProphylaxis of graft-versus-host disease gations showed no difference in incidence and severity of GVHD or overall survival. The University of Minnesota Concepts reported that ATG combined with methotrexate and predniMost preclinical modelling and clinical trials in GVHD sone reduced the incidence of GVHD from 48% (in patients have dealt with prophylaxis strategies. Effective prevention receiving methotrexate alone) to 21%. 20 Overall survival includes the use of histocompatible donors and recipients, and incidence of chronic GVHD, however, did not differ. the use of immunosuppressive drugs after the bone marrow
In the late 1970s the potent immunomodulator cyclosporinfusion, the in vitro manipulation of the donor graft, and ine (cyclosporine A), known as ciclosporin in Europe, and possibly housing the patient in a pathogen-poor, protected cyclosporin in Australia and New Zealand, was introduced. environment. 100 The agents in current use are much more Animal trials demonstrated this compound to be effective efficacious in preventing the cascade of immunologic in preventing GVHD, 109 and several uncontrolled clinical events we recognize as GVHD than in inactivating them trials indicated impressive results. [110] [111] [112] [113] [114] [115] [116] Other trials, howonce they are set in motion.
ever, prospectively comparing cyclosporine to methotrexate prophylaxis therapy, showed no differences, although each agent was superior to a 'no prophylaxis' strategy.
117-121
No GVHD prophylaxis The combination of cyclosporine and either methotrexate There have been only three small trials of transplants peror methylprednisolone appeared to decrease the incidence formed without GVHD prophylaxis and the results were of GVHD in several phase II and III studies. [122] [123] [124] [125] [126] [127] [128] [129] [130] [131] [132] Storb conflicting. [101] [102] [103] All three studies showed no difference in and associates 122 at the Fred Hutchinson Cancer Research survival in treated vs untreated patients. One study showed Center reported that in severe aplastic anemia patients no difference in incidence of GVHD, although both treated undergoing matched-sibling allogeneic bone marrow transand untreated patients exhibited very high rates of plantation, prophylaxis with cyclosporine and methotrexate GVHD; 101 the other two studies found more GVHD in the was associated with a significantly lower rate of grade IIuntreated patients.
102, 103 Sullivan et al 103 reported 'hyper-IV acute GVHD than use of single-agent methotrexate, acute GVHD', ie severe, explosive GVHD, in patients not 18% vs 53%. Although actuarial survival at 2 years after receiving prophylaxis. Although there is interest in avoidtransplant approached but did not reach statistical signifiing immunosuppression in low-risk patients using precance (82% vs 60%, P = 0.062), this group noted an screening in vitro testing, at present there is no evidence increase in infections in the methotrexate group, no differon which to recommend the absence of GVHD prophylaxis ences in the occurrence of chronic GVHD, and recin this group. 104 ommended combined therapy. In acute myeloid leukemia Two basic approaches to the prevention of GVHD have patients in first remission or chronic myeloid leukemia been utilized: post-transplant immunosuppressive drugs to patients in chronic phase receiving cyclosporine plus modify immune responses in the host, and lymphocyte methotrexate, the same group noted that the incidence of depletion of donor marrow. These two approaches will be grade II-IV GVHD was 33% as compared to those given considered separately. cyclosporine alone where the incidence was 54%. 126 A survival advantage was observed at 2 years in patients receiving combined cyclosporine and methotrexate. With Pharmacologic agents as GVHD prophylaxis additional follow-up, however, more relapses have occurred in the acute myeloid leukemia patients who received comCorticosteroids and other lympholytic chemotherapeutic drugs were among the first agents examined in animal modbined therapy, resulting in similar disease-free survival for both arms. 127, 128 els and subsequently in clinical trials. The choice of agents and timing of administration was modified by the particular At the Johns Hopkins Oncology Center patients were randomly assigned in double-blind fashion to receive either animal model used. Methotrexate was found to be the most potent agent in preventing and ameliorating GVHD in the cyclophosphamide and methylprednisolone, or cyclosporine and methylprednisolone.
129
The probability of canine model used by the group at the Fred Hutchinson Cancer Research Center, and hence they selected this agent developing acute GVHD was 68% in the cyclophosphamide arm and 32% in the cyclosporine arm; correspondingly, for clinical use. 105 Cyclophosphamide, which had the most potent effects in the rat model of GVHD used at the Johns survival in the cyclosporine arm was double that in the cyclophosphamide group. Similar results have been Hopkins Oncology Center was chosen for clinical use at that center. 106 Until the introduction of cyclosporine, reported in a phase II and a phase III trial.
130,131 Shepherd et al
130 observed a 28.5% rate of grade II-IV acute GVHD methotrexate or cyclophosphamide given in low-dose pulses after the bone marrow infusion were the mainstays of after 28 matched-related allografts with combined cyclosporine and methylprednisolone; they indicated that renal GVHD prophylaxis. Both were associated with a 25-50% toxicity was avoided by the use of this phase II combiOne of the current controversies is whether adding corticosteroids provides added benefit to the combination nation. The transplant team at the City of Hope reported a phase III study, in which patients were randomized to of cyclosporine and methotrexate; the results of these trials differ. [146] [147] [148] In one study, despite showing a benefit in receive methotrexate plus prednisone or cyclosporine plus prednisone. 131 Forty-seven percent of methotrexate-treated reduction of the incidence and severity of GVHD, infectious complications in the corticosteroid-treated group were patients developed GVHD compared to 28% in the cyclosporine group. Correcting for crossover of patients who significantly higher, further emphasizing the delicate balance between immunomodulation and immunosuppresdeveloped GVHD, a survival advantage was seen for cyclosporine-treated patients. In the three studies above, the incision. 147 On-going clinical trials may clarify the relative efficacy of the three-drug vs two-drug prophylactic dence of chronic GVHD did not decrease despite improvements in the prevention of acute GVHD. 122, [126] [127] [128] [129] [130] [131] Finally, regimens.
149
Another agent to enjoy a brief period of interest was in thalassemia patients undergoing allogeneic bone marrow transplantation, Galimberti and colleagues 132 reported that intravenous immunoglobulin (IVIG). IVIG has potential immunomodulatory and anti-infective effects. One trial the combination of cyclosporine, cyclophosphamide, and methotrexate was significantly more effective in preventing suggested that patients at high-risk for GVHD, such as older patients sero-positive for cytomegalovirus, would acute GVHD than cyclosporine used as single agent (41% vs 15%); event-free survival, however, did not differ in the benefit from IVIG therapy given prophylactically. 150 The high cost of this drug when given long-term and the negatwo groups. Table 3 illustrates the occurrence of acute and chronic tive results using survival as an endpoint in subsequent trials 151 may have dampened enthusiasm for better defining GVHD after prophylaxis using single and multiple immunosuppressive agents. These pooled data reflect only its role and mechanism of action.
Phillips et al 152 added the immunotoxin H65-RTA (antirandomized studies, and although the drugs are identical there were variations in dose and duration of therapy.
CD5-ricin A chain, see below) to a cyclosporine and methotrexate prophylaxis regimen in 31 patients receiving Additionally, the type and stage of diseases for which the transplant was conducted varied. The pooled data may be unrelated donor transplants, a group at extremely high risk for acute GVHD. All but two patients engrafted, and no late useful to indicate the lower incidence of grade II-IV acute GVHD with the use of combined immunosuppressants, graft failures were observed. Grade III-IV acute GVHD developed in only seven patients. This prophylaxis strategy although the risk of relapse correspondingly is increased.
Thus, there is considerable evidence that cyclosporine, appears to reduce the severity of acute GVHD but requires confirmation in larger studies. especially when given in combination with other agents, decreases the incidence and severity of acute GVHD after Limited data are available for another potent, specific immunomodulator, FK506 (tacrolimus). [153] [154] From a allogeneic bone marrow transplantation from histocompatible related donors. Although cyclosporine may have conmechanistic viewpoint, there is no reason to anticipate that FK506 will have an advantage over cyclosporine. 155, 156 Difsiderable side-effects, especially renal injury, and requires close monitoring of blood concentration, most bone marrow ferences exist, including the fact that hepatic metabolism of FK506 leads to higher concentrations in the liver, possibly transplant teams currently use cyclosporine plus a brief course of methotrexate as their standard GVHD prophylaxis explaining its advantage in allogeneic liver transplantation. One retrospective, single-center study, utilizing allogeneic regimen. [133] [134] [135] [136] [137] [138] [139] [140] The use of cyclosporine as a continuous infusion has been reported by one group to facilitate dose hematopoietic stem cells collected from the peripheral blood rather than bone marrow, suggested that FK506 may monitoring and possibly improve efficacy, and reduction of the dose of methotrexate may improve compliance and be more effective than cyclosporine in preventing GVHD, but additional data are needed. 154 reduce toxicity. [141] [142] On the other hand, combined cyclosporine and methotrexate appears to be less effective in New agents that appear promising in animal models are succinyl acetone, 15-deoxyspergualin, leflunomide, and unrelated donor transplants, and in situations in which the toxicities of the cytotoxic preparative regimen may preinterleukin-12. 157- 161 Clinical usefulness of these agents may be limited by irreversible cerebellar toxicity with succlude administration of full doses of cyclosporine and methotrexate. 29, [143] [144] [145] cinyl acetone and gastrointestinal toxicity with 15-deoxys- Table 3 The occurrence of acute and chronic GVHD after prophylaxis using single and combination immunosuppressive agents 160 Another agent, product had been cryopreserved at the time of harvest. In IL-12, appears to have promise in the prophylaxis of a retrospective study one group compared the use of 10 GVHD, although the only studies available to date are in matched, related allogeneic donor bone marrows which had mice. 161 This cytokine, a potent immunostimulatory cytobeen cryopreserved at the time of collection vs 33 matched kine and inducer of cytotoxic T lymphocyte function, related allogeneic bone marrow transplants which were inhibited the development of GVHD with a single injection.
infused fresh. 200 They noted no differences in time to Further studies of this paradoxical observation are warengraftment or blood product requirements, but the group ranted and will be noted with great interest. The reader is given cryopreserved donor marrow had less acute GVHD. referred to other reviews addressing pharmacologic agents These results have been updated to include 49 patients who in the prevention of GVHD. [162] [163] [164] were given cryopreserved (n = 31) or fresh (n = 16) bone marrow donations; grade II-IV acute GVHD rates were 37% and 50%, respectively. 201 The reasons for this difference are unclear, but offer an interesting research opportLymphocyte depletion of the donor graft as GVHD unity in this field. prophylaxis
The second major approach to prevent GVHD is lymphoConventional treatment of acute GVHD cyte depletion to remove effector cells from the donor graft. The removal of lymphocytes as well as other accessory
Primary therapy of established GVHD cells, however, can be associated with an increase in engraftment failure, or engraftment delay. On the other Despite prophylaxis, most patients develop acute and/or chronic GVHD. In the past, therapy for GVHD involved hand, as our understanding of GVHD has evolved, so has the appreciation that lymphocyte depletion may also the same agents as used for prophylaxis. 163, 164, [202] [203] [204] [205] [206] [207] The use of these agents, including glucocorticoids, antithymoremove many of the cells responsible for cytokines that mediate GVHD leading to disruption of the cytokine cascyte globulin, and cyclosporine, has been reviewed extensively. 72,208-217 Early after transplant, before hematopoietic cade and prevention/attenuation of the graft-versus-host reaction. This view is supported by the current interest in recovery, alloreactive T cells have not yet become fully expanded and differentiated. For this and other reasons, delayed infusion of donor lymphocytes, ie adoptive immunotherapy; this approach is associated with a potent graftsuch cells can be eliminated or inactivated more easily by immunosuppressives. This finding may explain why these versus-leukemia effect and a lower likelihood and severity of GVHD. [165] [166] [167] [168] [169] [170] [171] [172] [173] [174] [175] agents are more effective in preventing rather than treating established GVHD. 37 A variety of techniques have been used to deplete lymphocytes from the donor graft, including monoclonal antiDespite a number of significant complications such as avascular necrosis of bone (relative risk 6.3, P = 0.0002), body, chemical, and physical separation methods. [176] [177] [178] [179] [180] [181] [182] [183] [184] [185] [186] [187] [188] [189] [190] [191] [192] [193] [194] An overview is extremely difficult, since there is no standard corticosteroids form the backbone of most regimens for treatment of acute GVHD. 15, 218, 219 Weisdorf and co-workapproach. Relatively minor technical differences may make significant differences in clinical outcomes. Certain general ers 15 reported the long-term outcome of 197 patients treated for grade II-IV acute GVHD among 469 patients who principles, however, can be stated. All techniques are associated with a higher risk of engraftment failure, a compliunderwent allogeneic marrow transplant. Corticosteroid therapy alone was offered to 160 patients, while another 37 cated problem which may involve hematopoietic stem cell loss during marrow processing, lack of immunologic received other immunosuppressive agents. Complete response was attained in 72 patients (41%); another 61 potency to overcome residual host defenses, or a combination. This is an on-going area of investigation, including required subsequent therapy with high-dose corticosteroids and/or antithymocyte globulin; 64 patients died from varithe use of a novel, bone marrow-derived, engraftment 'facilitator cell' to compensate for increased risk of the lymphoous causes. In a more recent study, this group reported that of 510 patients treated, the response to primary therapy cyte depletion technique. [195] [196] [197] This donor bone marrow cell expresses a unique immunophenotype (positive for was one of the most important predictors for long-term survival.
219
CD8/CD3/CD45R/Thy 1/class II dim/intermediate yet T cell receptor negative) and can facilitate engraftment in MHCSome transplant centers begin with relatively low corticosteroid doses (ie 1 mg/kg/day prednisone disparate allogeneic recipients without causing GVHD. In preclinical systems larger numbers of hematopoietic stem equivalence) for patients presenting with limited cutaneous disease. High-dose glucocorticoid therapy usually is cells in the graft overcome this problem. In clinical situations, more intensive conditioning may be necessary.
reserved for patients with systemic or severe skin disease. Although the dose is variable and ranges up to 3 g/day Finally, lymphocyte-depleted grafts are associated with higher relapse rates, particularly in chronic myeloid leukeprednisone equivalence, many centers employ methylprednisolone in doses of 2.0-2.5 mg/kg/day. Although mia. 198 Weighing all of these factors makes comparisons of trials of lymphocyte depletion extremely difficult. This responses are obtained at very high doses, it is usually at the cost of severe catabolic damage, fluid retention, and review will not deal with this technique in detail.
hyperglycemia. Furthermore, the use of high-dose corticoincluded glucocorticoids (n = 249), cyclosporine (n = 80), antithymocyte globulin (n = 114), various monoclonal antisteroids will increase the risk of infection, but it is unclear to what extent. In one study in which corticosteroids were bodies (n = 19), either singly (n = 390) or in combination (n = 37). Improvement or resolution was observed in 45% used as GVHD prophylaxis in the early post-transplant period, the risk of infection was increased by 50%; 220 patients of patients with skin disease, 25% of patients with evaluable liver disease, and 35% of patients with evaluable gaswho have advanced GVHD are already at considerable risk for infection, and the benefit of controlling GVHD with trointestinal disease. Overall, complete or partial responses were noted in 40% of patients. The highest response rate corticosteroids may outweigh the drawbacks. After observing responses, corticosteroids generally are tapered every was observed when GVHD recurred during the taper phase of glucocorticoid therapy. When this group was excluded, 4-7 days. Hings and co-workers 221 randomized 30 patients who had moderate or severe GVHD responding within 14 responses to secondary treatment were considerably fewer. These data led the authors to recommend evaluating new days to primary corticosteroid therapy to a slow vs fast taper. Short-course prednisone consisted of 2275 mg/m 2 immunosuppressive agents in this setting with careful monitoring of the extent and severity of skin, intestinal, and administered over 86 days and the long taper regimen utilized 6300 mg/m 2 over 147 days. Patients given the brief liver organ dysfunction. course responded by 30 days (median), compared with 42 days in the other group (P = 0.01). Since the complications of corticosteroids, the incidence of chronic GVHD, and
Newer approved agents overall survival at 6 months were similar in both patient groups, these investigators favored a rapid taper. as with corticosteroid treatment. 209 Similarly, in animal models FK506 is effective in preCombinations of various immunosuppressives have been venting and treating GVHD. [229] [230] [231] [232] [233] [234] Published experiences used as GVHD treatment. 'Triple therapy' with prednisone, using FK506 to treat GVHD were limited, until recently, cyclosporine and anti-thymocyte globulin was found to be to two reports. 235, 236 Koehler et al 235 treated six children equally efficacious, but more toxic due to increased infecwith acute GVHD resistant to corticosteroids. Improvement tions, than therapy with antithymocyte globulin plus cycloin acute GVHD was observed in skin and gastrointestinal sporine alone. 210 Earlier, antithymocyte globulin and GVHD in all six patients, and liver GVHD in three of four corticosteroids were found to be equivalent in methotrexaffected patients. Toxicity, however, was significant and ate-treated patients. 215 The combination of prednisone and similar to that described for solid-organ transplant patients antithymocyte globulin was similarly ineffective in the treated with FK506. 224 Five patients had renal toxicity, and treatment of acute GVHD occurring in the setting of unretwo developed significant central nervous system injury. lated bone marrow transplantation. Roy et al 144 reported a Kanamaru and associates 236 studied 49 patients; 18 (13 high failure rate in unrelated marrow transplant patients, evaluable) had acute and 31 (26 evaluable) had chronic since only nine of 42 patients responded to prednisone and GVHD. A 'good' to marked response was noted in seven antithymocyte globulin by 100 days after transplant. More of 13 patients in the acute GVHD group. In the chronic recently, however, data for 267 HLA-A,B,D/DRB1-ident-GVHD group, 10 had a 'good' and two a marked response. ical and minor mismatched unrelated transplants from the As expected, renal injury (53%) and nausea and vomiting Fred Hutchinson Cancer Research Center showed no differ-(30%) were significant side-effects. These authors noted a ences in non-relapse mortality or survival compared to correlation of toxicity with whole blood FK506 concenmatched, related transplants when adjusted for age and tration, and recommended close monitoring for safety purdiagnosis. 222 poses. Further studies of this agent in the treatment of acute GVHD are warranted.
Secondary therapy of established GVHD
Initial treatment of GVHD remains unsatisfactory. Fewer than 50% of patients developing acute GVHD show durable Investigational and experimental therapies for GVHD improvement after initial treatment. Corticosteroid-resistant acute GVHD is extremely difficult to manage and is assoMonoclonal antibody therapy ciated with high morbidity and mortality. 15, 144, 218, 223 One commonly used salvage drug is antithymocyte globulin, Attempts at treating GVHD by infusion of monoclonal antibodies in vivo have met with limited success. 176 Early trials usually given in doses of 10-15 mg/kg every other day for 7-14 days. This agent provides effective anti-GVHD utilized antibodies directed against the effector cells, such as anti-T cell antibodies. In recent years, knowledge gained therapy in some patients but is quite toxic.
210,214-216
Martin et al 223 retrospectively analyzed secondary from understanding of the role of cytokines in GVHD pathophysiology has fostered the use of antibodies against therapy for acute GVHD in 427 patients without a durable response after primary treatment. Secondary treatment cytokines in experimental and clinical situations.
Anti-lymphocyte monoclonal antibody therapy days after transplant. One of the two patients given OKT3 for extensive chronic GVHD had a partial response, but both died (one due to aspergillosis and the other due to Reinherz et al 237 administered a unique, non-mitogenic anti-CD12 monoclonal antibody to a patient with combined chronic GVHD). BMA therapy was not associated with any toxicities. However, none of the seven patients given BMA immunodeficiency who developed refractory acute GVHD after undergoing a haploidentical mismatched transplant; treatment for grade II-III acute GVHD responded completely, although five had partial responses lasting 51 to the GVHD resolved after antibody therapy. Other trials used a mitogenic anti-CD3 agent with mixed results. [238] [239] [240] 1461+ days. Only one patient developed anti-isotypic or anti-idiotypic antibodies. Fatal infections occurred in sevThe cutaneous lesions in some patients responded to therapy, but only as long as the infusions were administered. eral patients. Neither agent appeared to have a sufficiently good therapeutic index to justify routine use. In a dose-escalation study Martin and co-workers 241 treated 24 patients who developed GVHD with an IgG 2a anti-CD3
Recently, Heslop and colleagues 246 reported encouraging results with CBL-1, the murine IgM monoclonal antibody murine monoclonal antibody, 64.1. In two patients the antibody was used as initial therapy of GVHD while in 22 directed against activated T cells and natural killer cells, which has been effective in reversing graft rejection in renal patients, it was given after failure of previous treatment. The antibody infusions were frequently associated with allografts. 247, 248 Nine of ten patients with grade III-IV corticosteroid-resistant GVHD responded within 2 weeks fever and chills. While skin GVHD in most patients responded to lower antibody doses, three-fold higher doses of treatment; five subjects had complete resolution, and marked response was noted in four others. The effect was were required to suppress GVHD affecting liver and intestine. No patients attained a complete response, and all durable, since only one partial and one complete responder had recurrence of acute GVHD. Although several patients needed additional immunosuppressive therapy. Furthermore, four patients developed Epstein-Barr virus (EBV)-died of relapse or subsequent infection, four subjects remain alive 89+ to 1173+ days after therapy (three with associated lymphoproliferative disorders within 7-18 days after initiating monoclonal antibody therapy.
238,241 These chronic GVHD). mitogenic anti-CD3 antibodies, combined with the severe immunosuppressive agents and the immunodeficiency of Anti-cytokine antibodies in treatment of GVHD GVHD, abrogated the T cell-mediated surveillance mechanism that normally modulates the proliferation of EBVAs early as 1971, it was postulated that endogenous cytokines played a role in GVHD. 249 Donor T lymphocytes infected lymphocytes.
Several investigators reported the successful use of nonappeared to be essential for GVHD; the development of syngeneic and autologous GVHD, however, ultimately led mitogenic anti-T cell antibodies without the development of lymphoproliferative disorders. [242] [243] [244] Remlinger et al 243 to a realization that IL-1, TNF-␣, IL-2, and other cytokines were extensively involved in the pathogenesis of GVHD used four monoclonal anti-T cell antibodies that reacted with mature T cells (pan T cell antibodies) to treat corticosreaction. [250] [251] [252] [253] As a result, some of the most promising results in the treatment of GVHD appear to be with the teroid-resistant acute GVHD. In this phase I study, six of 10 patients receiving intermediate to high doses of antibody newer monoclonal antibodies directed against the cytokines (TNF-␣ and IL-1), or the cytokine receptors involved in appeared to have some improvement in GVHD.
Anasetti and colleagues 244 reported the results of a phase the GVHD reaction (IL-1 soluble receptor, IL-2 soluble receptor). I-II study with a murine IgG 2b non-mitogenic anti-CD3 monoclonal antibody, termed BC3. Fourteen patients with GVHD were given BC3 at a dose of 0.1-0.2 mg/kg/day IL-1 and antagonists for 7 or 8 days. Side-effects included mild chills, fever, hypertension, and chest discomfort. Eight patients IL-1 is a central cytokine in the activation of T cells and in the pathogenesis of GVHD. 254 IL-1 production occurs responded, five completely and three partially. Although responses were sustained in most patients and four of the early in the inflammatory process and leads to increased expression of TNF-␣ and other cytokines. 255 , 256 Abhyankar complete responders had effects lasting longer than 1 year, most patients died of infection.
et al 257 used competitive polymerase chain reaction technique to measure cytokine mRNA transcripts in GVHD tarHebart and colleagues 245 reported results of treatment with two murine monoclonal antibodies in 14 patients who get organs. They noted that in the setting of GVHD, IL-1 mRNA was elevated several hundred-fold in the skin and developed severe corticosteroid-resistant GVHD. These antibodies included OKT3, an IgG 2a directed against one other target organs, while TNF-␣ transcripts increased only four-to six-fold, and IL-2 transcripts were elevated only of the CD3 subunit complexes, and BMA031, an IgG 2b directed against an epitope in the constant region of the transiently and slightly. While these data are interesting, they must be interpreted with caution in view of the comhuman ␣/␤ T cell receptor. Seven patients were given OKT3 as a single agent, five for acute GVHD and two for petitive assay technique used to provide quantitation. In mice, McIntyre and colleagues 258 infused the recombinant chronic GVHD. The first injections were associated with fever, chills, tachycardia, dyspnea, and hypotension. Three human IL-1 receptor antagonist and 35F5, a neutralizing monoclonal antibody to the type I mouse IL-1 receptor and of five who received therapy for grade II-IV acute GVHD responded completely. One of the responders (grade IV blocked the local accumulation of neutrophils and the acute inflammatory responses to intraperitoneal injections of GVHD) died of aspergillosis; the two others with grade II and III GVHD remain alive, free of GVHD 628+ and 720+
IL-1 and lipopolysaccharide. 271, 272 retrospectively described elevated serum levels of TNF-␣ in patients who developed acute GVHD antagonists were effective both as prophylaxis and treatment of GVHD. Hematopoietic reconstitution was not and other complications such as capillary-leak syndrome and hepatic veno-occlusive disease. In a prospective study affected and mortality from GVHD was reduced. Recent data from a preclinical mouse model, however, were disapof over 100 patients, increased serum TNF-␣ correlated with increased severity of GVHD and other problems such pointing, since IL-1 receptor antagonists did not completely inhibit GVHD when donor bone marrow was fully MHC as hepatic veno-occlusive disease. 61 Equally important, the timing of the elevation in serum TNF-␣ predicted subdisparate. 260 Protection was significant but only partial despite the use of extremely high doses. The authors consequent development of severe complications and overall survival, ie those patients who developed increases before cluded that intervention with a single cytokine antagonist might be insufficient to render a lasting protective effect marrow infusion as a result of the preparative regimen had a 90% chance of developing GVHD and fewer than 30% and urged caution in the conduct of clinical trials using a similar design.
of these patients survived. Although a causal relationship between TNF-␣ and GVHD has not been established Since IL-1 receptor antagonists were shown to have some efficacy in experimental animal systems, various unequivocally, such high-risk patients theoretically could benefit from anti-TNF-␣ antibody infusions. This approach clinical trials were initiated. Antin and co-workers 261 conducted a phase I/II trial to evaluate the effectiveness of an is currently being investigated in prospective trials. Several trials address the use of anti-TNF-␣ monoclonal IL-1 receptor antagonist in 16 patients who had severe, corticosteroid-resistant GVHD. They infused antibody as a antibodies in the treatment of GVHD. Hervé and associates [273] [274] [275] [276] [277] studied the murine IgG 1 monoclonal antibody 24-h continuous infusion over 7 days, and escalated the dose from 400 to 3200 mg/day. Improvement was noted in (B-C7) in 24 patients with resistant grade III-IV GVHD.
Patients were given 0.1-0.4 mg/kg antibody in six doses the skin (8/14) , gastrointestinal tract (9/11), and liver (2/11). Lack of response of hepatic GVHD may reflect difover 8 days and no side-effects were observed. Although there were no complete responses, 17 patients had a partial ficulties in measuring response in the liver, differential responses, or other hepatic toxicities during marrow transresponse. Gastrointestinal and skin GVHD responded best, but some patients experienced improvement in hepatic plantation such as veno-occlusive disease and drug toxicity. Acute GVHD was improved by at least one grade in 10 of GVHD. GVHD recurred (in all but three patients) a median of 3 days (range: 2-120 days) after discontinuing therapy. 16 patients. In addition, the improvement in acute GVHD co-incided with a reduction in TNF-␣ mRNA levels in These three patients with a sustained response remain alive 7, 13 and 15 months after transplant. Four other patients blood mononuclear cells. The toxicity profile of the IL-1 receptor antagonist was acceptable, the only adverse effect remain alive, but most patients died from GVHD. Holler et al 272, 278 reported preliminary results of infusing either Bbeing reversible serum transaminase elevation in two patients. These data corroborate the data generated in C7 (n = 22) or MAK 195 F, a murine F(ab) 2 fragment of an anti-TNF-antibody (n = 8) in resistant GVHD. Therapy experimental animal systems that IL-1 is a mediator of GVHD. Although acute GVHD did not resolve in all was well tolerated, rapid improvement was noted in affected organs in two-thirds to three-quarters of patients, but patients, the results of this phase I/II study are important and may justify a larger trial using the maximal effective symptoms recurred quickly after cessation of therapy. These studies indicate that TNF-␣ is an effector of human dose of drug.
acute GVHD. However, they also demonstrate that modulation of cytokines alone may be insufficient to interrupt Tumor necrosis factor and antagonists ongoing immunologic activation in advanced GVHD. Results might be better if reagents such as anti-TNF-␣ are TNF-␣ is a macrophage-derived cytokine with multistimulatory effects on T cells and an important mediator of the used earlier in the course of GVHD or prophylactically, or in combination with immune suppressive agents. 272 inflammatory process. TNF-␣ has also been implicated in the pathogenesis of GVHD. [262] [263] [264] [265] [266] TNF-␣ infusion mimics most manifestations of GVHD in experimental animal sys-IL-2 and antagonists tems. 264 In one preclinical study polyclonal or monoclonal anti-TNF-␣ antibody prevented GVHD, 264 but in another 260 IL-2 also appears to play a role in the pathogenesis of GVHD. Theobald et al 279 demonstrated that the number of TNF-␣ antagonists, even at high doses, were not effective. In two studies Dickinson et al 267, 268 used an in vitro skin donor T cells that secrete IL-2 in response to host antigens will accurately predict development of GVHD after a histoexplant model to test the role of different cytokines in development of GVHD. They showed that supernatant from compatible sibling-matched transplant. Alessandrine et al 280 and Siegert et al 281 found a correlation between incimixed lymphocyte cultures contained factors which induced features in the skin grafts identical to those seen in dence of GVHD and raised serum concentrations of soluble IL-2 receptor complex. The immunosuppressive activity of GVHD in vivo. Antibodies to TNF-␣ and interferon (IFN)-gamma reduced these changes. They also demonstrated such antibodies may reflect both blocking of IL-2 binding and IL-2-dependent T cell proliferation as well as destrucmarked synergy between TNF-␣ and interferon-gamma, as has been demonstrated in other situations. 269 Loetscher 270 tion of IL-2 receptor-positive cells. 282 Since soluble cytokine receptors or antagonists can be cloned, it may be possdemonstrated that a recombinant TNF-␣ receptor can ible competitively to inhibit the biological activity of the monoclonal antibody (B-B10) directed against the IL-2 receptor. 277, 293 The patient population included 31 patients cytokine by preventing IL-2 from reaching its receptor, without developing neutralizing antibodies. This strategy with grade II GVHD, 21 with grade III GVHD, and six with grade IV GVHD. In the course of this phase I-II study may also be useful for receptors for IL-4 and TNF-␣, which also have been cloned recently. patients were given 75-100 mg antibody over 20 days without any toxic effects reported. Twenty-nine of 58 patients Two clinical studies evaluated the benefits of prophylaxis with an antibody to soluble IL-2 receptor. Belanger et (50%) had complete resolution of GVHD; these responses included 19/31 with grade II GVHD, 8/21 grade III GVHD al 283-284 administered the anti-IL-2 receptor monoclonal antibody 33B31 to 64 patients undergoing matched, unreand 2/6 grade IV GVHD. An additional 12 patients achieved a partial response for a total of 41 responders in 58 lated allogeneic marrow transplantation, along with methotrexate and cyclosporine. No toxic effects were noted but treated patients; 17 of these patients (41%) had recurrence of GVHD. Twenty-six of 58 remain alive 240-900 days neither were there differences in incidence and time of onset of severe GVHD, occurrence of chronic GVHD, after antibody therapy, while 16 have died from GVHDrelated causes. The investigators have indicated that a phase engraftment, relapse, or survival when compared to a historical control group of 89 patients. Tiley and co-workers 285 III trial evaluating this antibody is underway. In addition, these investigators reported the use of the B-B10 antibody treated 31 allograft patients with GVHD using a murine monoclonal IgG 1 anti-IL-2 receptor antibody (B-B10, also in 25 partially matched and matched-unrelated transplant patients who developed GVHD. 277 The patient population known as BT 563). Thirty patients received matched-sibling marrow, and one received marrow from a matched included 14 patients with grade II GVHD, nine with grade III GVHD and two with grade IV GVHD. Complete resolunrelated donor. Seventeen patients responded completely and six partially, but GVHD recurred within a median of ution of GVHD was observed in 15 patients (n = 10 grade II; n = 4 grade III; n = 2 grade IV GVHD). Another six 10 days after completion of anti-IL-2 receptor antibody therapy in 12 patients.
patients exhibited a partial response to therapy, for a total of 21 of 25 responders (88%). GVHD, however, recurred Cuthbert and colleagues 286 treated 14 corticosteroidresistant patients with a murine monoclonal anti-IL-2 recepwithin 2-30 days after cessation of antibody therapy in nine of the 21 responders. Thirteen patients remain alive, while tor antibody (termed BT 563, also known as B-B10) which reacts with the p55 epitope. No toxic effects directly 15 died from GVHD-related causes; the best results occurred in those patients given the B-B10 antibody earlier attributable to the antibody were noted. Eight patients responded, four attaining a complete and four a partial in the course of their GVHD. Hervé et al 275, 276 reported in preliminary fashion the use response. One complete responder developed chronic GVHD and died of infection 4 months after therapy. Three of the B-B10 monoclonal antibody in 99 heterogeneous allogeneic transplant patients who had steroid-resistant complete responders who had grade III or IV GVHD, however, remain alive without GVHD 4, 5 and 7 months after GVHD. Similar data were noted as above, since GVHD recurred in nearly half the cases within 2-30 days after therapy. Cahn and co-workers 287 completed a doubleblinded, placebo-controlled, multicenter trial using the BT discontinuation of monoclonal antibody therapy. Also, GVHD affecting the liver responded poorly to this therapy. 563 monoclonal anti-IL-2 receptor antibody to treat 69 patients who developed grade II and III GVHD. No statistiThis reagent, however, has definite activity in the treatment of GVHD, especially if therapy is instituted soon after cally significant differences were observed between the two groups during or upon completion of therapy in GVHD onset. In addition, monitoring of other parameters such as soluble CD8 and TNF-␣ predict a positive response to antigrade or probability of survival at 1 year.
Based on a successful preclinical animal model in which IL-2 therapy. 294 These studies suggest a role for this antibody in combination therapy. Ferrara et al 288 reduced the severity of GVHD by injections of an anti-IL-2 receptor monoclonal antibody, several cliniAnasetti and co-workers 295, 296 reported the use of several preparations of anti-IL-2 receptor antibodies. They reported cal GVHD prophylaxis trials have been done. Blaise et al [289] [290] [291] reported their results using 33B31, a rat IgG 2a antithe use of 2A3, a murine IgG 1 monoclonal antibody specific for the IL-2 binding site (CD25) in 11 corticosteroid-refrac-IL-2 receptor monoclonal antibody in genotypically identical and one antigen-mismatched sibling bone marrow tory patients. 295 Antibody was given as 0.1-1.0 mg/kg/day for 7 days. Toxic effects included fever, chills, respiratory transplant patients. All patients received GVHD prophylaxis with cyclosporine, 'short course' methotrexate, and distress, hypertension, hypotension, and four patients developed human anti-mouse antibodies. Anti-GVHD daily intravenous infusions of anti-CD25 monoclonal antibody. No major adverse effects were noted and engraftment responses were seen in four patients: a complete response in one patient who had skin only disease, and partial did not appear to be delayed. No human anti-rat antibodies were noted. Grade II-III GVHD developed in four patients responses in three patients in the skin and intestine. No responses were observed in the liver and only one of the 32-40 days after marrow infusion. These disappointing results with prophylactic use of this antibody suggest it to responding patients survived more than 2 months from the start of antibody treatment. These modest results may be of limited value.
In 1988 Hervé et al 292 reported that a monoclonal antireflect either the severity of the disease or the development of human anti-mouse neutralizing antibodies. body against the IL-2 receptor was effective as therapy for established GVHD in 10 patients. Subsequently, 58 patients Advances in technology allowed the development of a more fully humanized, less immunogenic monoclonal antiwho developed corticosteroid-resistant GVHD after a sibling-matched allograft were treated with an IgG 1 murine body, termed anti-TAC. 297 Humanized anti-TAC is a gen-etically engineered human IgG 1 monoclonal antibody spetreated group (148 days) compared to only 80 days in the historical control group. Despite these results this agent has cific for the IL-2 receptor ␤ chain (CD25) which blocks the IL-2-dependent activation of human T lymphocytes.
not been approved for use in bone marrow transplantation by the US Food and Drug Administration. Twenty patients who had failed corticosteroids as primary therapy for GVHD were treated with single doses of antibody in cohorts of 0.5, 1.0 or 1.5 mg/kg antibody;
Combination anti-lymphocyte and anti-cytokine responding patients could receive additional antibody thermonoclonal antibody therapy apy. 296, 298 Therapy was well tolerated since only chills (one patient) and diaphoresis (one patient) were noted during One group devised a novel strategy in which three monoclonal antibodies were used in sequence as therapy for or shortly after antibody infusion. No patients developed a measurable antibody response to therapy. Improvement in corticosteroid-resistant acute GVHD. 304 The murine IgG 1 anti-TNF-␣ monoclonal antibody (B-C7) was given for 4 GVHD was noted in eight patients (four complete and four partial responses), including amelioration in three of 15 days along with the murine IgG 2b anti-CD2 (B-E2) monoclonal antibody (derived against human thymocytes) for 10 patients with GVHD affecting the liver. One complete responder did not develop chronic GVHD and is alive 645 days, followed by the murine IgG 1 monoclonal anti-IL-2r antibody B-B10 (renamed BT563). Fifteen patients who days later off all immunosuppressives; the seven other responders later developed chronic GVHD, and one patient had steroid-resistant acute GVHD underwent therapy, including six subjects who had grade II GVHD, two grade is alive 529 days later.
III, and seven grade IV disease. Five patients had a complete response while four experienced a significant but Immunotoxins incomplete response to therapy. GVHD, however, recurred in four of these responding patients despite continued treatImmunoconjugates have been used in a variety of situations as therapy for GVHD and have been reviewed. 299 After the ment. This group demonstrated the tolerance of multiple monoclonal antibody therapy and the potential of combinreport of successful treatment using one agent, H65-RTA, (XomaZyme; XOMA Corporation, Berkeley, CA, USA), a ing antibodies that have differing mechanisms of action. more extensive experience has been reported. 300 This immunoconjugate was the first drug of its type introduced Thalidomide (N-phatalidoglutarimide) for clinical immunosuppression. It was developed to combine an anti-CD5 murine monoclonal antibody, which will Thalidomide was originally developed as a sedative but was observed to have anti-inflammatory and immunosuppresreact with an antigen present on 95% of peripheral T cells, with ricin A chain, a potent toxin. A phase I trial was consive properties; in 1961 this agent was withdrawn from clinical use because of its teratogenic effects. 305, 306 ducted in 34 patients who had corticosteroid-refractory acute GVHD. 301 Nine patients attained a complete Recently, thalidomide has received attention as a treatment for GVHD. [307] [308] [309] [310] [311] Thalidomide exerts its action via several response, while seven achieved partial responses. No patients died of GVHD within the first 100 days after thermechanisms, including direct immunosuppressive properties and inhibition of TNF-␣ production as well as the apy, and the duration of response was for at least 100 days. Skin and intestinal GVHD responded most favorably, but induction of antigen-specific suppressor cells. 307, 308, [312] [313] [314] Thalidomide therapy has been associated with sedation in some patients experienced improvement in liver GVHD. Circulating lymphocyte numbers decreased with drug virtually all patients treated; some patients develop a peripheral neuropathy which resolves with cessation of drug. administration but returned to baseline with cessation of the infusions. A variety of side-effects were reported, including Thalidomide has been most effective in the treatment of chronic rather than acute GVHD. [315] [316] [317] [318] fever, chills, arthralgias, depression, lethargy, fatigue, transient hypoalbuminemia, and weight gain. While renal dysfunction was observed, this toxic effect could not be linked Interferons directly to the immunoconjugate, since most patients were already receiving nephrotoxic agents. Interestingly, while IFN-gamma appears to play a role in GVHD. Smith et al 319 used a mouse model to demonstrate that IFN-gamma is a six patients developed human anti-mouse antibodies, in no instance did these agents interfere with binding of the mediator of the immunosuppressive activity of GVHD of the spleen. Niederwieser and colleagues 320 noted that immunoconjugate to CD5 cells, and no allergic reactions developed. Subsequent trials comparing this agent to hisendogenous levels of IFN-gamma preceded the clinical onset of GVHD. Furthermore, in a murine model, antitorical controls have been reported in preliminary fashion. 302, 303 Seventy-five corticosteroid-refractory patients bodies to IFN-gamma provided protection to the gut. 321 Thus, based on these initial preclinical results, there may were given H65-RTA and 18 (24%) patients attained a complete response, while 21 (28%) had a partial response be justification for considering anti-IFN-gamma antibodies in expanded animal studies, and possibly in a prospective of GVHD. While responses occurred in all affected organs, the skin responses were twice as frequent as those noted clinical trial. in the liver, and intestinal GVHD results were midway in frequency. Overall, 39 of 75 patients (52%) responded to Nitric oxide this approach, whereas only 31% of a matched historical control population responded to antithymocyte globulin Nitric oxide appears to be a short-lived biological mediator that plays an important role in host defense and macrophage treatment. Similarly, the median survival was better in the 325 used another murine allogeneic minor histoincompatibility transplant model to evaluate the New agents effect of the same nitric oxide synthase inhibitor. Amelioration of GVHD by inhibition of nitric oxide synthase early after transplant was suggested by their data, but this was Some of the newest and more novel agents which could or not conclusive. On the other hand, use of L-N G monomethyl have shown promise in the treatment of GVHD are listed arginine adversely affected alloengraftment, which would in Table 4 . be a great concern were this approach to be used in a clinical situation. Additional animal trials are needed before considering the use of this agent in clinical trials.
Rapamycin Anti-adhesion molecules Rapamycin, originally discovered as an antifungal agent, is an immunosuppressive drug similar to cyclosporine and Recent work has suggested that blockade of cell adhesion FK-506 although its action occurs later in T cell activation. molecules may effectively block cell/cell interactions, It inhibits T cell activation by interfering with signals thereby interfering with recognition, signaling, and other induced by the T cell growth factors IL-2 and IL-4. 338, 339 facets of the GVHD reaction at the cellular level. Harning In a recent report Quesniaux and colleagues 340 showed in and associates 326 studied two antibodies to the cellular vitro that this agent blocks the proliferative responses of a adhesion molecules LFA-1␣ (CD11a) and MALA-2 (the number of cell lines and bone marrow progenitors to many murine homologue of ICAM-1). Mice given anti-LFA-1␣ cytokines, including IL-1, IL-3, IL-6, IL-11, G-CSF, GMantibody (M17/4.2) or anti-MALA-2 (YN1/1.7) experi-CSF, and stem cell factor. While they noted that rapamycin enced significantly reduced GVHD and enhanced survival.
suppressed hematopoietic recovery in mice given cytotoxic LeDeist et al 327 transplanted 10 leukocyte adhesion drugs, it had no effect on myelopoiesis in normal mice. deficiency patients using T cell depleted HLA-non-identical
In a murine experimental model, rapamycin prolonged the transplants, yet graft rejection did not occur. These results survival of recipients of allogeneic donor grafts when suggested that host T cells and natural killer cells, which administered during the GVHD process. 341 This agent lack the LFA-1 antigen, poorly interact with donor marrow appears to be a general inhibitor of cytokine-driven procells. Van Dijken et al 328 administered five daily infusions liferation and ultimately may be too toxic for use in patients of anti-LFA-1 antibody early after transplant to mice given who have recently undergone high-dose therapy. It may be incompatible T cell-depleted marrow and demonstrated a useful, however, in treating GVHD in some subjects in low incidence of engraftment failure. These experimental whom the bone marrow appears to function adequately, or data indicate that use of anti-adhesion molecules may have in whom regimen-related toxicity is not a problem. a role in either facilitating engraftment in high-risk situations for engraftment failures, or in abrogating GVHD.
Class II peptide binding molecules Photopheresis therapy of GVHD
Several groups have used photopheresis in the treatment of Antigen-specific T cell activation occurs when the T cell receptor recognizes antigenic peptide fragments bound to GVHD. [329] [330] [331] [332] [333] [334] [335] [336] [337] Ex vivo treatment of patient blood after in vivo treatment with 8-methoxypsoralen inactivates self molecules encoded by the major histocompatibility complex (MHC). 342 CD8 + T cells recognize peptides comimmunocompetent lymphocytes to diminish the manifestation of GVHD. This approach has often been employed plexed to class I MHC molecules, and CD4 + T cells recognize peptides in association with class II MHC molin patients with GVHD limited to skin. [329] [330] [331] [332] [333] [334] [335] [336] [337] The sample sizes have usually been small, but many of patients ecules. 343 It has been possible to design molecules which interfere with the MHC-peptide-T cell-receptor triad, responded to this intervention. In one of the larger series, Deeg et al 335 reported their experiences in 18 patients who resulting in prevention of distinct T cell-mediated autoimmune diseases. [344] [345] [346] Based, in part, on the work cited failed to respond to prednisone alone or in combination with an anti-CD5 immunotoxin (n = 13), or antithymocyte above, Schlegel et al 343 showed that the administration of peptides (myelin basic protein residues) with high binding globulin (n = 5). Patients were given 1-32 treatments with 8-methoxypsoralen followed by ultraviolet A irradiation affinity for class II MHC molecules prevented GVHD in mice undergoing transplantation across minor histocompat-(PUVA). Ten patients responded and did not require additional therapy for acute GVHD. In a recent study, ibility barriers. This approach may be potentially useful for the prevention and treatment of GVHD in allogeneic bone Aubin and co-workers 337 reported 11 patients with acute and chronic GVHD predominantly of skin, which was marrow transplant patients. 347 reported the unsuccessful use of 2-a variety of T cell-mediated reactions in mice. They noted chlorodeoxyadenosine in two patients who had corticosthat this immunotoxin blocked delayed-type hypersensitivteroid-refractory GVHD. The infusion was well-tolerated ity and selectively eliminated the targeted T cells from but significant myelosuppression occurred in both patients. draining lymph nodes. Kuzel et al 351 reported a phase I Both patients died of GVHD without response to 2-chlorodstudy in which the diphtheria IL-2 fusion protein eoxyadenosine. Both deaths were from intestinal GVHD 11 DAB 486 IL-2 was used as an anti-tumor agent against and 49 days after starting therapy. Considering the potent mycosis fungoides and non-Hodgkin's lymphomas. and sustained immunosuppressive effects of this agent, it Although untested to date, this strategy has the potential to is doubtful that 2-chlorodeoxyadenosine will play a sigbe useful in the treatment of GVHD in humans. nificant role in the therapy of established acute GVHD.
Desferrioxamine

Mycophenolic acid
The iron chelator desferrioxamine inhibits IL-2 receptor This agent, which is a potent and specific inhibitor of the expression on phytohemagglutinin-stimulated lymphocytes synthesis of guanosine nucleotides and thus a selective supin vitro. In a preliminary communication Michallet and pressor of proliferation of both T and B lymphocytes, has associates 348 reported the results of desferrioxamine used as been used for the prevention of rejection in human renal therapy for GVHD in conjunction with methylprednisolone. and liver transplantation. [352] [353] [354] [355] This agent has not yet been Seventeen of 18 patients with skin GVHD responded; six used to any great extent in clinical allogeneic bone marrow of nine with intestinal and seven of 10 with liver GVHD transplant trials, but may receive added interest in view of responded. Reversible ototoxicity and ocular toxicity was its unique mechanism of action and extensive experience noted, along with transient thrombocytopenia. This novel in solid-organ transplantation. approach may merit further consideration in prospective, randomized fashion.
IL-10 Penicillamine
Summerfield and co-workers 349 reported a patient who This cytokine possesses both anti-inflammatory as well as immunosuppressive properties, in part by inhibiting proreceived penicillamine for sclerodermatous chronic GVHD. The syndrome was previously resistant to both corticosterduction of IFN-gamma and TNF-␣. 356, 357 In a parental-to-F 1 mouse model, IL-10 did not prevent lethal GVHD but oids and azathioprine. After treatment with penicillamine, skin ulcers and joint contractures resolved completely. The reduced clinical manifestations due to cytokine mediators such as IFN-gamma and TNF-␣. 358 Clinical trials using ILreport of a successful outcome in one patient who received penicillamine therapy may be sufficient justification for 10 in allogeneic transplantation have not yet been initiated but will be watched with great interest. further study. 
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